Listed

Maravai Lifesciences Holdings, Inc.

MRVINasdaqCIK 1823239HealthcareFiscal year ends Dec 31

Latest reported revenue, Q2 FY2026$51.4mRevenue, Q2 FY2026, three months to 2026-06-30$51.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-07, accession 0001823239-26-000059.Report this figureThree months to Jun 30, 2026, from the 10-Q filed Aug 7, 2026.

Latest quarter: Q2 FY2026

Three months to Jun 30, 2026, against the same quarter a year earlier.

  • Revenue$51.4mRevenue, Q2 FY2026, three months to 2026-06-30$51.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-07, accession 0001823239-26-000059.Report this figure+8.5% on a year earlier
  • Gross margin40.1%Gross margin, Q2 FY2026, three months to 2026-06-30. gross profit / revenueGross profit: $20.6m. XBRL concept us-gaap:GrossProfit. 10-Q filed 2026-08-07, accession 0001823239-26-000059.Revenue: $51.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-07, accession 0001823239-26-000059.Report this figure+23.8 pts on a year earlier
  • Operating margin−29.3%Operating margin, Q2 FY2026, three months to 2026-06-30. operating income / revenueOperating income: −$15.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-07, accession 0001823239-26-000059.Revenue: $51.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-07, accession 0001823239-26-000059.Report this figure+110.5 pts on a year earlier
  • Net margin−24.1%Net margin, Q2 FY2026, three months to 2026-06-30. net income / revenueNet income: −$12.4m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-07, accession 0001823239-26-000059.Revenue: $51.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-07, accession 0001823239-26-000059.Report this figure+59.4 pts on a year earlier
  • Diluted EPS−$0.08Diluted EPS, Q2 FY2026, three months to 2026-06-30−$0.08 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-07, accession 0001823239-26-000059.Report this figure+70.4% on a year earlier
  • Free cash flow$3.6mFree cash flow, Q2 FY2026, three months to 2026-06-30. operating cash flow − capital expenditureOperating cash flow: $4.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-07, accession 0001823239-26-000059. Derived: 6-month figure less the 3-month figure.Capital expenditure: $370.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-07, accession 0001823239-26-000059. Derived: 6-month figure less the 3-month figure.Report this figureSign changed from a year earlier

Last eight quarters

Full statements
Revenue$51.4mGross margin 40.1%
Diluted EPS−$0.08, Q2 FY2026
Free cash flow$3.6m, Q2 FY2026
Maravai Lifesciences Holdings, Inc., key figures for the last eight quarters
Line itemUnitQ3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30Shape over the periods
Revenue$m69.0Revenue, Q3 FY2024, three months to 2024-09-30$69.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-07, accession 0001823239-25-000120.Report this figure56.6Revenue, Q4 FY2024, three months to 2024-12-31$56.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001823239-26-000011. Derived: 12-month figure less the 9-month figure.Report this figure46.9Revenue, Q1 FY2025, three months to 2025-03-31$46.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-08, accession 0001823239-26-000024.Report this figure47.4Revenue, Q2 FY2025, three months to 2025-06-30$47.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-07, accession 0001823239-26-000059.Report this figure41.6Revenue, Q3 FY2025, three months to 2025-09-30$41.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-07, accession 0001823239-25-000120.Report this figure49.9Revenue, Q4 FY2025, three months to 2025-12-31$49.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001823239-26-000011. Derived: 12-month figure less the 9-month figure.Report this figure65.8Revenue, Q1 FY2026, three months to 2026-03-31$65.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-08, accession 0001823239-26-000024.Report this figure51.4Revenue, Q2 FY2026, three months to 2026-06-30$51.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-07, accession 0001823239-26-000059.Report this figure
Gross margin%46.7%Gross margin, Q3 FY2024, three months to 2024-09-30. gross profit / revenueGross profit: $32.2m. XBRL concept us-gaap:GrossProfit. 10-Q filed 2025-11-07, accession 0001823239-25-000120.Revenue: $69.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-07, accession 0001823239-25-000120.Report this figure34.3%Gross margin, Q4 FY2024, three months to 2024-12-31. gross profit / revenueGross profit: $19.4m. XBRL concept us-gaap:GrossProfit. 10-K filed 2026-02-26, accession 0001823239-26-000011. Derived: 12-month figure less the 9-month figure.Revenue: $56.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001823239-26-000011. Derived: 12-month figure less the 9-month figure.Report this figure16.5%Gross margin, Q1 FY2025, three months to 2025-03-31. gross profit / revenueGross profit: $7.7m. XBRL concept us-gaap:GrossProfit. 10-Q filed 2026-05-08, accession 0001823239-26-000024.Revenue: $46.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-08, accession 0001823239-26-000024.Report this figure16.4%Gross margin, Q2 FY2025, three months to 2025-06-30. gross profit / revenueGross profit: $7.8m. XBRL concept us-gaap:GrossProfit. 10-Q filed 2026-08-07, accession 0001823239-26-000059.Revenue: $47.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-07, accession 0001823239-26-000059.Report this figure13.6%Gross margin, Q3 FY2025, three months to 2025-09-30. gross profit / revenueGross profit: $5.7m. XBRL concept us-gaap:GrossProfit. 10-Q filed 2025-11-07, accession 0001823239-25-000120.Revenue: $41.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-07, accession 0001823239-25-000120.Report this figure25.8%Gross margin, Q4 FY2025, three months to 2025-12-31. gross profit / revenueGross profit: $12.8m. XBRL concept us-gaap:GrossProfit. 10-K filed 2026-02-26, accession 0001823239-26-000011. Derived: 12-month figure less the 9-month figure.Revenue: $49.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001823239-26-000011. Derived: 12-month figure less the 9-month figure.Report this figure51.2%Gross margin, Q1 FY2026, three months to 2026-03-31. gross profit / revenueGross profit: $33.7m. XBRL concept us-gaap:GrossProfit. 10-Q filed 2026-05-08, accession 0001823239-26-000024.Revenue: $65.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-08, accession 0001823239-26-000024.Report this figure40.1%Gross margin, Q2 FY2026, three months to 2026-06-30. gross profit / revenueGross profit: $20.6m. XBRL concept us-gaap:GrossProfit. 10-Q filed 2026-08-07, accession 0001823239-26-000059.Revenue: $51.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-07, accession 0001823239-26-000059.Report this figure
Operating margin%(239.9%)Operating margin, Q3 FY2024, three months to 2024-09-30. operating income / revenueOperating income: −$165.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-07, accession 0001823239-25-000120.Revenue: $69.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-07, accession 0001823239-25-000120.Report this figure(66.7%)Operating margin, Q4 FY2024, three months to 2024-12-31. operating income / revenueOperating income: −$37.7m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-26, accession 0001823239-26-000011. Derived: 12-month figure less the 9-month figure.Revenue: $56.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001823239-26-000011. Derived: 12-month figure less the 9-month figure.Report this figure(104.9%)Operating margin, Q1 FY2025, three months to 2025-03-31. operating income / revenueOperating income: −$49.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-08, accession 0001823239-26-000024.Revenue: $46.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-08, accession 0001823239-26-000024.Report this figure(139.8%)Operating margin, Q2 FY2025, three months to 2025-06-30. operating income / revenueOperating income: −$66.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-07, accession 0001823239-26-000059.Revenue: $47.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-07, accession 0001823239-26-000059.Report this figure(98.6%)Operating margin, Q3 FY2025, three months to 2025-09-30. operating income / revenueOperating income: −$41.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-07, accession 0001823239-25-000120.Revenue: $41.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-07, accession 0001823239-25-000120.Report this figure(117.9%)Operating margin, Q4 FY2025, three months to 2025-12-31. operating income / revenueOperating income: −$58.8m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-26, accession 0001823239-26-000011. Derived: 12-month figure less the 9-month figure.Revenue: $49.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001823239-26-000011. Derived: 12-month figure less the 9-month figure.Report this figure(3.3%)Operating margin, Q1 FY2026, three months to 2026-03-31. operating income / revenueOperating income: −$2.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-08, accession 0001823239-26-000024.Revenue: $65.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-08, accession 0001823239-26-000024.Report this figure(29.3%)Operating margin, Q2 FY2026, three months to 2026-06-30. operating income / revenueOperating income: −$15.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-07, accession 0001823239-26-000059.Revenue: $51.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-07, accession 0001823239-26-000059.Report this figure
Net margin%(140.6%)Net margin, Q3 FY2024, three months to 2024-09-30. net income / revenueNet income: −$97.1m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-07, accession 0001823239-25-000120.Revenue: $69.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-07, accession 0001823239-25-000120.Report this figure(45.8%)Net margin, Q4 FY2024, three months to 2024-12-31. net income / revenueNet income: −$25.9m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-26, accession 0001823239-26-000011. Derived: 12-month figure less the 9-month figure.Revenue: $56.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001823239-26-000011. Derived: 12-month figure less the 9-month figure.Report this figure(63.9%)Net margin, Q1 FY2025, three months to 2025-03-31. net income / revenueNet income: −$29.9m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-05-08, accession 0001823239-26-000024.Revenue: $46.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-08, accession 0001823239-26-000024.Report this figure(83.5%)Net margin, Q2 FY2025, three months to 2025-06-30. net income / revenueNet income: −$39.6m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-07, accession 0001823239-26-000059.Revenue: $47.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-07, accession 0001823239-26-000059.Report this figure(61.4%)Net margin, Q3 FY2025, three months to 2025-09-30. net income / revenueNet income: −$25.6m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-07, accession 0001823239-25-000120.Revenue: $41.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-07, accession 0001823239-25-000120.Report this figure(71.6%)Net margin, Q4 FY2025, three months to 2025-12-31. net income / revenueNet income: −$35.7m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-26, accession 0001823239-26-000011. Derived: 12-month figure less the 9-month figure.Revenue: $49.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001823239-26-000011. Derived: 12-month figure less the 9-month figure.Report this figure(5.7%)Net margin, Q1 FY2026, three months to 2026-03-31. net income / revenueNet income: −$3.7m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-05-08, accession 0001823239-26-000024.Revenue: $65.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-08, accession 0001823239-26-000024.Report this figure(24.1%)Net margin, Q2 FY2026, three months to 2026-06-30. net income / revenueNet income: −$12.4m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-07, accession 0001823239-26-000059.Revenue: $51.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-07, accession 0001823239-26-000059.Report this figure
Diluted EPS$ per share(0.68)Diluted EPS, Q3 FY2024, three months to 2024-09-30−$0.68 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-07, accession 0001823239-25-000120.Report this figurenot reported (Diluted EPS not reported)(0.21)Diluted EPS, Q1 FY2025, three months to 2025-03-31−$0.21 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-08, accession 0001823239-26-000024.Report this figure(0.27)Diluted EPS, Q2 FY2025, three months to 2025-06-30−$0.27 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-07, accession 0001823239-26-000059.Report this figure(0.18)Diluted EPS, Q3 FY2025, three months to 2025-09-30−$0.18 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-07, accession 0001823239-25-000120.Report this figurenot reported (Diluted EPS not reported)(0.02)Diluted EPS, Q1 FY2026, three months to 2026-03-31−$0.02 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-08, accession 0001823239-26-000024.Report this figure(0.08)Diluted EPS, Q2 FY2026, three months to 2026-06-30−$0.08 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-07, accession 0001823239-26-000059.Report this figure
Free cash flow$m4.5Free cash flow, Q3 FY2024, three months to 2024-09-30. operating cash flow − capital expenditureOperating cash flow: $13.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-07, accession 0001823239-25-000120. Derived: 9-month figure less the 6-month figure.Capital expenditure: $8.6m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-07, accession 0001823239-25-000120. Derived: 9-month figure less the 6-month figure.Report this figure(20.5)Free cash flow, Q4 FY2024, three months to 2024-12-31. operating cash flow − capital expenditureOperating cash flow: −$14.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-26, accession 0001823239-26-000011. Derived: 12-month figure less the 9-month figure.Capital expenditure: $5.8m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-26, accession 0001823239-26-000011. Derived: 12-month figure less the 9-month figure.Report this figure(13.9)Free cash flow, Q1 FY2025, three months to 2025-03-31. operating cash flow − capital expenditureOperating cash flow: −$9.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-08, accession 0001823239-26-000024.Capital expenditure: $4.5m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-08, accession 0001823239-26-000024.Report this figure(13.1)Free cash flow, Q2 FY2025, three months to 2025-06-30. operating cash flow − capital expenditureOperating cash flow: −$10.3m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-07, accession 0001823239-26-000059. Derived: 6-month figure less the 3-month figure.Capital expenditure: $2.9m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-07, accession 0001823239-26-000059. Derived: 6-month figure less the 3-month figure.Report this figure(18.8)Free cash flow, Q3 FY2025, three months to 2025-09-30. operating cash flow − capital expenditureOperating cash flow: −$15.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-07, accession 0001823239-25-000120. Derived: 9-month figure less the 6-month figure.Capital expenditure: $3.7m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-07, accession 0001823239-25-000120. Derived: 9-month figure less the 6-month figure.Report this figure(24.9)Free cash flow, Q4 FY2025, three months to 2025-12-31. operating cash flow − capital expenditureOperating cash flow: −$22.8m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-26, accession 0001823239-26-000011. Derived: 12-month figure less the 9-month figure.Capital expenditure: $2.1m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-26, accession 0001823239-26-000011. Derived: 12-month figure less the 9-month figure.Report this figure4.2Free cash flow, Q1 FY2026, three months to 2026-03-31. operating cash flow − capital expenditureOperating cash flow: $8.7m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-08, accession 0001823239-26-000024.Capital expenditure: $4.4m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-08, accession 0001823239-26-000024.Report this figure3.6Free cash flow, Q2 FY2026, three months to 2026-06-30. operating cash flow − capital expenditureOperating cash flow: $4.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-07, accession 0001823239-26-000059. Derived: 6-month figure less the 3-month figure.Capital expenditure: $370.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-07, accession 0001823239-26-000059. Derived: 6-month figure less the 3-month figure.Report this figure

Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.

Last five fiscal years

Revenue$185.7mGross margin 18.3%
Diluted EPS−$0.90, FY2025
Free cash flow−$70.7m, FY2025
Maravai Lifesciences Holdings, Inc., key figures for the last five fiscal years
Line itemUnitFY20212021-12-31FY20222022-12-31FY20232023-12-31FY20242024-12-31FY20252025-12-31Shape over the periods
Revenue$m799Revenue, FY2021, twelve months to 2021-12-31$799.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2024-02-29, accession 0001823239-24-000032.Report this figure883Revenue, FY2022, twelve months to 2022-12-31$883.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-03-18, accession 0001823239-25-000034.Report this figure289Revenue, FY2023, twelve months to 2023-12-31$288.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001823239-26-000011.Report this figure259Revenue, FY2024, twelve months to 2024-12-31$259.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001823239-26-000011.Report this figure186Revenue, FY2025, twelve months to 2025-12-31$185.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001823239-26-000011.Report this figure
Gross margin%not reported (Gross profit not reported)not reported (Gross profit not reported)48.5%Gross margin, FY2023, twelve months to 2023-12-31. gross profit / revenueGross profit: $140.2m. XBRL concept us-gaap:GrossProfit. 10-K filed 2026-02-26, accession 0001823239-26-000011.Revenue: $288.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001823239-26-000011.Report this figure41.8%Gross margin, FY2024, twelve months to 2024-12-31. gross profit / revenueGross profit: $108.3m. XBRL concept us-gaap:GrossProfit. 10-K filed 2026-02-26, accession 0001823239-26-000011.Revenue: $259.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001823239-26-000011.Report this figure18.3%Gross margin, FY2025, twelve months to 2025-12-31. gross profit / revenueGross profit: $34.0m. XBRL concept us-gaap:GrossProfit. 10-K filed 2026-02-26, accession 0001823239-26-000011.Revenue: $185.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001823239-26-000011.Report this figure
Operating margin%69.4%Operating margin, FY2021, twelve months to 2021-12-31. operating income / revenueOperating income: $554.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2024-02-29, accession 0001823239-24-000032.Revenue: $799.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2024-02-29, accession 0001823239-24-000032.Report this figure65.0%Operating margin, FY2022, twelve months to 2022-12-31. operating income / revenueOperating income: $574.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2025-03-18, accession 0001823239-25-000034.Revenue: $883.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-03-18, accession 0001823239-25-000034.Report this figure(11.0%)Operating margin, FY2023, twelve months to 2023-12-31. operating income / revenueOperating income: −$31.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-26, accession 0001823239-26-000011.Revenue: $288.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001823239-26-000011.Report this figure(90.9%)Operating margin, FY2024, twelve months to 2024-12-31. operating income / revenueOperating income: −$235.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-26, accession 0001823239-26-000011.Revenue: $259.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001823239-26-000011.Report this figure(115.9%)Operating margin, FY2025, twelve months to 2025-12-31. operating income / revenueOperating income: −$215.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-26, accession 0001823239-26-000011.Revenue: $185.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001823239-26-000011.Report this figure
Net margin%22.8%Net margin, FY2021, twelve months to 2021-12-31. net income / revenueNet income: $182.0m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2024-02-29, accession 0001823239-24-000032.Revenue: $799.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2024-02-29, accession 0001823239-24-000032.Report this figure24.9%Net margin, FY2022, twelve months to 2022-12-31. net income / revenueNet income: $220.2m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2025-03-18, accession 0001823239-25-000034.Revenue: $883.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-03-18, accession 0001823239-25-000034.Report this figure(41.2%)Net margin, FY2023, twelve months to 2023-12-31. net income / revenueNet income: −$119.0m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-26, accession 0001823239-26-000011.Revenue: $288.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001823239-26-000011.Report this figure(55.9%)Net margin, FY2024, twelve months to 2024-12-31. net income / revenueNet income: −$144.8m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-26, accession 0001823239-26-000011.Revenue: $259.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001823239-26-000011.Report this figure(70.4%)Net margin, FY2025, twelve months to 2025-12-31. net income / revenueNet income: −$130.8m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-26, accession 0001823239-26-000011.Revenue: $185.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001823239-26-000011.Report this figure
Diluted EPS$ per share1.56Diluted EPS, FY2021, twelve months to 2021-12-31$1.56 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2024-02-29, accession 0001823239-24-000032.Report this figure1.67Diluted EPS, FY2022, twelve months to 2022-12-31$1.67 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2025-03-18, accession 0001823239-25-000034.Report this figure(0.90)Diluted EPS, FY2023, twelve months to 2023-12-31−$0.90 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-02-26, accession 0001823239-26-000011.Report this figure(1.05)Diluted EPS, FY2024, twelve months to 2024-12-31−$1.05 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-02-26, accession 0001823239-26-000011.Report this figure(0.90)Diluted EPS, FY2025, twelve months to 2025-12-31−$0.90 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-02-26, accession 0001823239-26-000011.Report this figure
Free cash flow$m354Free cash flow, FY2021, twelve months to 2021-12-31. operating cash flow − capital expenditureOperating cash flow: $368.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2024-02-29, accession 0001823239-24-000032.Capital expenditure: $14.8m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2024-02-29, accession 0001823239-24-000032.Report this figure519Free cash flow, FY2022, twelve months to 2022-12-31. operating cash flow − capital expenditureOperating cash flow: $536.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2025-03-18, accession 0001823239-25-000034.Capital expenditure: $17.1m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2025-03-18, accession 0001823239-25-000034.Report this figure60.7Free cash flow, FY2023, twelve months to 2023-12-31. operating cash flow − capital expenditureOperating cash flow: $126.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-26, accession 0001823239-26-000011.Capital expenditure: $65.6m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-26, accession 0001823239-26-000011.Report this figure(22.2)Free cash flow, FY2024, twelve months to 2024-12-31. operating cash flow − capital expenditureOperating cash flow: $7.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-26, accession 0001823239-26-000011.Capital expenditure: $29.7m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-26, accession 0001823239-26-000011.Report this figure(70.7)Free cash flow, FY2025, twelve months to 2025-12-31. operating cash flow − capital expenditureOperating cash flow: −$57.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-26, accession 0001823239-26-000011.Capital expenditure: $13.1m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-26, accession 0001823239-26-000011.Report this figure

Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.

Insider purchases and sales

All insider transactions

The last 20 open-market transactions reported on Form 4 (codes P and S). The reported price is the price per share the insider stated on the form: filing data, not a market price.

No open-market purchases or sales by insiders are in coverage from Nov 2024 to Oct 2026.

No open-market purchases or sales by insiders are in coverage for this company.

Funds that report holding it

All funds

From each manager's latest Form 13F, largest reported value first. Reported value is as filed at the quarter end: filing data, not a price. A put or call is an option position, not shares held.

Funds that report holding Maravai Lifesciences Holdings, Inc.
FundQuarter endedReported valueSharesPut or callChange on the quarter before
GTCR LLC2026-06-30$125.7m20,150,005Unchanged
BlackRock, Inc.2026-06-30$62.2m9,970,780Added+625,512
BRAIDWELL LP2026-06-30$54.3m8,702,921Reduced−1,537,243
12 West Capital Management LP2026-06-30$44.1m7,060,195Reduced−200,000
MILLENNIUM MANAGEMENT LLC2026-06-30$40.6m6,508,220Added+4,858,730
VANGUARD CAPITAL MANAGEMENT LLC2026-06-30$33.0m5,283,665Reduced−166,037
Ophir Asset Management Pty Ltd2026-06-30$30.1m4,826,698New+4,826,698
RENAISSANCE TECHNOLOGIES LLC2026-06-30$28.7m4,606,491Added+341,802
DEUTSCHE BANK AG\2026-06-30$26.9m4,304,927Added+3,446,672
First Eagle Investment Management, LLC2026-06-30$22.9m3,671,287Added+1,146,951

Recent filings

All 419 filings

Reports and events: 10-K, 10-Q, 8-K, proxy statements and ownership schedules.

Maravai Lifesciences Holdings, Inc., recent filings
FiledFormWhat it isAccession number
2026-08-0720:03 ET10-QQuarterly reportPeriod 2026-06-300001823239-26-000059
2026-08-0620:05 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0001823239-26-000056
2026-06-0312:31 ET8-K1.01 Entry into a material agreement; 1.02 Termination of a material agreement; 2.03 New direct financial obligation; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits0001823239-26-000049
2026-05-2920:19 ET8-K5.07 Shareholder vote results0001823239-26-000046
2026-05-0820:30 ET10-QQuarterly reportPeriod 2026-03-310001823239-26-000024
2026-05-0720:05 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0001823239-26-000022
2026-04-2420:29 ETDEF 14AProxy statementPeriod 2026-05-260001823239-26-000014
2026-02-2621:06 ET10-KAnnual reportPeriod 2025-12-310001823239-26-000011
2026-02-2521:05 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0001823239-26-000005
2025-11-0721:21 ET10-QQuarterly reportPeriod 2025-09-300001823239-25-000120

Latest annual report

Form 10-K for the fiscal year ended Dec 31, 2025Filed Feb 26, 2026. Its page lists the documents and the extracted sections, such as Business and Risk factors.

Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by [object Promise].Forecast this quarter

About the filer

CIK
1823239
Tickers
MRVI
Exchange
Nasdaq
SIC code
2834 Pharmaceutical Preparations
Sector
Healthcare
Fiscal year ends
Dec 31
Incorporated in
DE
Filer category
Accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:48 ET. Listed shows no prices and gives no investment advice.